X

Trial Profile

Phase II Study of Neoadjuvant Chemotherapy of Gemcitabine+Nab-paclitaxel Therapy for Patients With Borderline Resectable Pancreatic Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Therapeutic Use
Acronyms NAC-GA trial

Most Recent Events

28 Sep 2020 Planned End Date changed from 1 Sep 2021 to 4 Oct 2021.
28 Sep 2020 Status changed from recruiting to active, no longer recruiting.
08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com